Vanguard Group
MBX

Vanguard Group’s MBX Biosciences MBX Stock Holding History

Vanguard Group’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$57.3M Buy
1,817,811
+140,449
+8% +$3.41M ﹤0.01% 2090
2025
Q3 		$29.4M Buy
1,677,362
+633,678
+61% +$8.47M ﹤0.01% 2435
2025
Q2 		$11.9M Buy
1,043,684
+378,121
+57% +$3.85M ﹤0.01% 2808
2025
Q1 		$4.91M Sell
665,563
-5,385
-0.8% -$56.9K ﹤0.01% 3178
2024
Q4 		$12.4M Buy
670,948
+620,948
+1,242% +$13.2M ﹤0.01% 2835
2024
Q3 		$1.3M Buy
+50,000
New +$1.14M ﹤0.01% 3695

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group's MBX Position: Q4 2025 in Review

Vanguard Group increased its MBX Biosciences (MBX) stake by 8.4% in Q4 2025, buying an estimated $3.41M and bringing the position to 1,817,811 shares worth $57.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2090.

Vanguard Group first reported a position in MBX in Q3 2024 and has held it in 6 quarters since. 138 funds tracked by Wall St. Rank hold MBX as of Q4 2025.

  • Vanguard Group held 1,817,811 shares of MBX Biosciences worth $57.3M as of Q4 2025.
  • Vanguard Group bought 140,449 MBX Biosciences shares in Q4 2025, an estimated $3.41M.
  • MBX Biosciences made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2090 holding.
  • Vanguard Group first reported a position in MBX Biosciences in Q3 2024 and has held it in 6 quarters since.
  • 138 funds tracked by Wall St. Rank held MBX Biosciences as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.